Method of judging imflammatory disease by using single nucleotide polymorphism in galectin -2 gene
AssigneesToshihiro Tanaka, Yozo Ohnishi, Kouichi Ozaki, Aritoshi Iida, Masatsugu Hori, Riken
InventorsToshihiro Tanaka, Yozo Ohnishi, Kouichi Ozaki, Aritoshi Iida, Masatsugu Hori, Yusuke Nakamura
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to identify a novel single nucleotide polymorphism (SNP) associated with the onset and development of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging inflammatory diseases which comprises detecting at least one gene polymorphism in the galectin-2 gene.
Claims13
A method for judging inflammatory diseases which comprises detecting at least one gene polymorphism in the galectin-2 gene.
A method for analyzing the state of galectin-2 expression which comprises detecting the C/T polymorphism at nucleotide 3279 in the nucleotide sequence of intron 1 of the galectin-2 gene as shown in SEQ ID NO:
- 1.
A method for screening for a therapeutic agent for inflammatory diseases which comprises steps of analyzing the expression level of the galectin-2 or galectin-1 genes in cells in the presence of a candidate substance and selecting a substance that alters such expression level.
A method for screening for a therapeutic agent for inflammatory diseases which comprises steps of analyzing the expression level of the galectin-2 or galectin-1 genes in cells in the presence of a candidate substance and selecting a substance that increases such expression level.
A method for screening for a therapeutic agent for inflammatory diseases which comprises steps of assaying the binding between lymphotoxin-α (LTA) and the gene product of galectin-2 or galectin-1 in the presence of a candidate substance and selecting a substance that inhibits such binding.
Dependencies are inferred from the claim text.